New and emerging biomarkers in left ventricular systolic dysfunction–insight into dilated cardiomyopathy.

Link to article at PubMed

Related Articles

New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.

J Cardiovasc Transl Res. 2013 Aug;6(4):516-27

Authors: Gopal DM, Sam F

Dilated cardiomyopathy (DCM) is characterized by deteriorating cardiac performance, impaired contraction and dilation of the left ventricle (or both ventricles). Blood markers--known as "biomarkers"--allow insight into underlying pathophysiologic mechanisms and biologic pathways while predicting outcomes and guiding heart failure management and/or therapies. In this review, we provide an alternative approach to conceptualize heart failure biomarkers: the cardiomyocyte, its surrounding microenvironment, and the macroenvironment, integrating these entities which may impact cellular processes involved in the pathogenesis and/or propagation of DCM. Newer biomarkers of left ventricular systolic dysfunction can be categorized under: (a) myocyte stress and stretch, (b) myocyte apoptosis, (c) cardiac interstitium, (d) inflammation, (e) oxidative stress, (f) cardiac energetics, (g) neurohormones, and (h) renal biomarkers. Biomarkers provide insight into the pathogenesis of DCM while predicting and potentially providing prognostic information in these patients with heart failure.

PMID: 23609585 [PubMed - indexed for MEDLINE]

Leave a Reply

Your email address will not be published.